VANCOUVER, British Columbia, March 14, 2022 (GLOBE NEWSWIRE) — Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced the successful completion of 28-day repeat-dose toxicity studies for its lead product…


Previous articlePT301 – Kabir Ali – Addiction, Ketamine, and the Overlooked Gift of Self-Love
Next articleNova Mentis Announces Closing of Non-Brokered Financing